Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver enhanced anti-cancer activity. The company’s product pipeline includes VYXEOS, a nano-scale liposomal formulation of irinotecan:floxuridine, which is in Phase III clinical testing for the treatment of acute myeloid leukemia; CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase III study for the treatment of acute myeloid leukemia; and ...
200 PrincetonSouth Corporate Center
Ewing, NJ 08628
Founded in 1999
Celator Pharmaceuticals, Inc. Files Form 15
Jul 22 16
Celator Pharmaceuticals, Inc. announced that it has filed Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock of par value $0.001 per share under the Securities Exchange Act of 1934, as amended.
Celator Pharmaceuticals, Inc.(NasdaqGM:CPXX) dropped from NASDAQ Composite Index
Jul 13 16
Celator Pharmaceuticals, Inc. has been removed from Nasdaq Composite Index.
Celator Pharmaceuticals, Inc. Requests NASDAQ To Remove Listing Of Shares; Intends To File Form 15
Jul 12 16
As previously disclosed in the Current Report on Form 8-K filed by Celator Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission (SEC) on May 31, 2016, the company entered into an Agreement and Plan of Merger, dated as of May 27, 2016 among the company, Jazz Pharmaceuticals plc (Parent), and Plex Merger Sub, Inc. (Purchaser). Pursuant to the Merger Agreement, on June 10, 2016, Purchaser commenced a tender offer to purchase all of the outstanding shares of the company’s common stock, par value $0.001 per share. On July 12, 2016, Parent announced the completion of the Offer. On July 12, 2016, on the terms and subject to the conditions set out in the Merger Agreement and in accordance with Section 251(h) of the Delaware General Corporation Law, Purchaser was merged with and into the company, with the company continuing as the surviving corporation. Upon completion of the Merger, the company became an indirect wholly-owned subsidiary of Parent. On July 12, 2016, in connection with the consummation of the Merger, the company notified The NASDAQ Capital Market that the Merger had been consummated, and requested that the trading of shares on NASDAQ be halted prior to market open on July 12, 2016 and that such trading be suspended and the listing of the shares on NASDAQ be removed, in each case, prior to market open on July 12, 2016. In addition, the company requested that NASDAQ file with the SEC an application on Form 25 to delist the shares from NASDAQ and to deregister the shares under Section 12(b) of the Securities Exchange Act of 1934, as amended. The company intends to file with the SEC a Certification and Notice of Termination on Form 15 requesting the deregistration of the shares under Section 12(g) of the Exchange Act and the suspension of the company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.